{"created":"2021-03-01T07:08:00.059044+00:00","id":29506,"links":{},"metadata":{"_buckets":{"deposit":"d2d1360d-9850-4967-a1d1-37f049f57056"},"_deposit":{"id":"29506","owners":[],"pid":{"revision_id":0,"type":"depid","value":"29506"},"status":"published"},"_oai":{"id":"oai:tsukuba.repo.nii.ac.jp:00029506","sets":["117:811","3:62:5592:1842"]},"item_5_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2013-11","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"143","bibliographicPageStart":"137","bibliographicVolumeNumber":"172","bibliographic_titles":[{"bibliographic_title":"Journal of controlled release"}]}]},"item_5_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"吉冨, 徹"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"長崎, 幸夫"}],"nameIdentifiers":[{},{},{}]}]},"item_5_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The ultimate goal of cancer chemotherapy is to achieve a cure without causing any adverse effects. We have developed a pH-sensitive redox nanoparticle (RNPN), which disintegrates under acidic conditions and exposes nitroxide radicals, leading to strongly scavenging reactive oxygen species (ROS). After intravenous administration of RNPN to tumor bearing mice, it effectively accumulated in tumors due to the leaky neovascular and immature lymphatic system and scavenged ROS, resulting in suppression of inflammation and activation of NF-кB, after disintegration of RNPN in the tumors. Pre-administration of RNPN prior to treatments with anticancer agents, doxorubicin, to tumor-bearing mice significantly suppressed the progression of tumor size, compared to low-molecular weight 4-hydroxy-TEMPO. Interestingly, the administration of RNPN suppressed adverse effects of doxorubicin to normal organs due to the scavenging ROS and suppression of inflammation, which was confirmed by reduction in lactate dehydrogenase and creatine phosphokinase activities in plasma. RNPN is thus anticipated as a novel and ideal adjuvant for cancer chemotherapy.","subitem_description_type":"Abstract"}]},"item_5_identifier_34":{"attribute_name":"URI","attribute_value_mlt":[{"subitem_identifier_type":"HDL","subitem_identifier_uri":"http://hdl.handle.net/2241/120846"}]},"item_5_publisher_27":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Elsevier B.V."}]},"item_5_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"23958903","subitem_relation_type_select":"PMID"}}]},"item_5_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"10.1016/j.jconrel.2013.08.011","subitem_relation_type_select":"DOI"}}]},"item_5_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2013 Elsevier B.V.　NOTICE: this is the author’s version of a work that was accepted for publication in Journal of Controlled Release. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in Journal of Controlled Release, 172, 1, 2013         http://dx.doi.org/10.1016/j.jconrel.2013.08.011"}]},"item_5_select_15":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_select_item":"author"}]},"item_5_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"0168-3659","subitem_source_identifier_type":"ISSN"}]},"item_5_source_id_9":{"attribute_name":"書誌レコードID","attribute_value_mlt":[{"subitem_source_identifier":"AA10458678","subitem_source_identifier_type":"NCID"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"Yoshitomi, Toru"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Ozaki, Yuki"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Thangavel, Sindhu"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"Nagasaki, Yukio"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2014-05-09"}],"displaytype":"detail","filename":"JCR_172-1.pdf","filesize":[{"value":"2.4 MB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"JCR_172-1.pdf","url":"https://tsukuba.repo.nii.ac.jp/record/29506/files/JCR_172-1.pdf"},"version_id":"bbfff3eb-e580-4aa9-b737-0a1bb02daa6f"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"Redox nanoparticle therapeutics to cancer — increase in therapeutic effect of doxorubicin, suppressing its adverse effect","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Redox nanoparticle therapeutics to cancer — increase in therapeutic effect of doxorubicin, suppressing its adverse effect"}]},"item_type_id":"5","owner":"1","path":["811","1842"],"pubdate":{"attribute_name":"公開日","attribute_value":"2014-02-20"},"publish_date":"2014-02-20","publish_status":"0","recid":"29506","relation_version_is_last":true,"title":["Redox nanoparticle therapeutics to cancer — increase in therapeutic effect of doxorubicin, suppressing its adverse effect"],"weko_creator_id":"1","weko_shared_id":5},"updated":"2022-04-27T08:57:59.153636+00:00"}